Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Infrainguinal Occlusive Disease Treatment & Management

  • Author: Christian Ochoa, MD; Chief Editor: Vincent Lopez Rowe, MD  more...
 
Updated: Apr 08, 2015
 

Medical Therapy

Most patients with atherosclerotic lower-extremity disease do not undergo surgical treatment. In fact, only 25% of patients presenting with intermittent claudication eventually require invasive treatment of limb-threatening ischemia or intractable symptoms, and only 5-10% do so within 5 years of the onset of claudication.

The cornerstones of medical management of intermittent claudication are walking and elimination or control of medical risk factors.[28, 29] (See also Noncoronary Atherosclerosis and Coronary Artery Atherosclerosis.)

Walking

Encourage walking.[30] Regular walking of approximately 1 hour per day usually results in a significant increase in walking distance over time. This increase in walking distance has been noted to range from 80% to more than 200%. Improvement results from improved flow in collateral pathways.

Risk factor management

A major factor contributing to progressive and intractable atherosclerotic disease is cigarette smoking. One study noted an 85% chance of improvement if smoking is stopped versus only a 20% chance of improvement if the patient continues smoking.

Other medical risk factors that must be assessed and controlled are obesity, hypertension, hyperlipidemia, and diabetes.[31]

Because an ischemic foot is at risk for developing limb-threatening ulceration from even minor trauma, good foot hygiene and appropriately fitting shoes are important. This is even more vital for patients with diabetes, who are also at risk for neuropathic foot ulcers.

Pharmacotherapy

Currently available drugs that may benefit patients with mild or moderate claudication include pentoxifylline and cilostazol.[32, 33] Controlled studies suggest that each of these drugs improves walking distance by approximately 20% more than placebo, cilostazol perhaps slightly more than pentoxifylline.

Cilostazol, administered at 100 mg orally twice daily, has demonstrated some benefit for claudication symptoms.[34] Cilostazol is contraindicated in patients with congestive heart failure,[35] as noted in the product's black box warning.

Pentoxifylline, 400 mg orally 3 times per day taken with meals, has been available for many years. After 2-3 months of use, 25-60% of patients demonstrate some improvement in walking distance. However, much of this improvement may be attributable to exercise and to modification of the risk factors mentioned above. The major adverse effects of this medication are gastrointestinal in nature.

Antiplatelet agents (eg, aspirin, clopidogrel), angiotensin-converting enzyme inhibitors, and statins should also be considered.

Caveats regarding pharmacotherapy are that vasodilators and chelation therapy have no demonstrated benefit in the treatment of claudication. Beta-blocking agents may worsen claudication and must be discontinued, if medically feasible.

Next

Surgical Therapy

Surgical or endovascular intervention is indicated for intractable and disabling claudication, for ischemic pain at rest, and for ischemic necrosis. Surgery also may be useful for nonhealing ischemic ulceration.

Before considering surgical intervention, the clinician must address the possibility of coexisting atherosclerotic heart and cerebrovascular disease, which are extremely common in patients with atherosclerotic peripheral arterial disease. One study found that only 14% of patients with peripheral arterial disease had normal coronary arteries, whereas 15% had severe coronary artery disease that required surgical correction. (See Atherosclerosis for the cardiologic workup.)

Patients with a prior ipsilateral peripheral endovascular intervention have been found to have a higher likelihood of a poor outcome when undergoing lower-extremity bypass for critical limb ischemia.[36] Reported 1-year amputation and graft occlusion rates have been higher in these patients than those who have not undergone prior revascularization procedures (eg, prior ipsilateral bypass). These factors can help determine revascularization options in patients with critical limb ischemia.[36]

However, Uhl et al carried out a retrospective analysis comparing patients who had undergone tibial or peroneal bypass surgery for critical limb ischemia after prior endovascular interventions with patients who had received a tibial or peroneal bypass as a primary revascularization procedure because primary endovascular therapy had been considered unfeasible.[37] They found that prior endovascular intervention in femorotibial vessels did not negatively affect the outcome of subsequent tibial or peroneal bypass surgery.

A British study reports that the major amputation rate after femorodistal bypass remains high, with adverse events occurring after approximately 38% of femoropopliteal procedures and nearly 50% of femorodistal bypasses. The main predictors of a poor outcome reportedly were diabetes and chronic renal failure.[38]

Obtain appropriate imaging studies. Before surgical intervention, the exact extent of the atherosclerotic disease is mapped by using high-quality contrast angiography (see Imaging Studies).

In recognition of the importance of the pathologic anatomy in decision making, the Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC) published a set of guidelines for treatment of lower extremity peripheral arterial disease (see Table 2 below).[39]

Table 2. TASC Classification for Femoral Popliteal Lesions (Open Table in a new window)

Type Description
Type A lesions
  • Single lesions ≤10 cm in length
  • Single occlusions ≤5 cm in length
Type B lesions
  • Multiple lesions (stenoses or occlusions), each ≤5 cm
  • Single stenosis or occlusion ≤15 cm not involving the infrageniculate popliteal artery
  • Single or multiple lesions in the absence of continuous tibial vessels to improve inflow for a distal bypass
  • Heavily calcified occlusion ≤5 cm in length
  • Single popliteal stenosis
Type C lesions
  • Multiple stenoses or occlusions totaling >15 cm with or without heavy calcification
  • Recurrent stenoses or occlusions that need treatment after two endovascular interventions
Type D lesions
  • Chronic total occlusions of common femoral artery or superficial femoral artery (>20 cm, involving the popliteal artery)
  • Chronic total occlusion of popliteal artery and proximal trifurcation vessels

 

The general recommendations are endovascular approach for TASC type A lesions and open surgery for TASC type D lesions. Insufficient data are available on type B and C lesions; however, type B lesions are probably best treated endovascularly and type C lesions best treated with open surgery.

Previous
Next

Preoperative Details

Prior to vascular surgery, a routine laboratory workup is performed, including complete blood count, biochemical profile, clotting studies, urinalysis, chest radiography, and electrocardiography (ECG). Abnormalities are addressed.

Although some suggest discontinuing clopidogrel preoperatively to minimize intraoperative bleeding risks, one analysis suggests that this is not necessary and that clopidogrel therapy can be safely continued.[40]

Radiographic contrast

If an endovascular procedure is to be performed, iodinated contrast material is required, and hence, one must check for renal insufficiency, a history of contrast allergy, and the use of metformin (see Imaging Studies).

Infection prevention

Take appropriate measures to prevent vascular graft infection. For routine prophylaxis in bypass surgery, a broad-spectrum antibiotic (eg, a broad-spectrum cephalosporin, a penicillin/beta-lactamase inhibitor, or an aminoglycoside) is administered just before surgery and postoperatively for one to three doses. If there is known colonization with or local prevalence of methicillin-resistant Staphylococcus aureus (MRSA), consider vancomycin or teicoplanin.[41]

Consider a preoperative antiseptic shower or scrub.

Patients harboring a potential infection (eg, foot ulcer or gangrene) may fare better having the infected tissue excised, even with limited amputations, prior to vascular intervention in order to avoid graft or wound infections.

Urgent intervention

If urgent intervention is required, the workup may have to be truncated. In the case of acute arterial occlusion, the workup may have to be minimal because prompt thrombectomy is often required for limb salvage. Preoperative angiography may still be warranted, especially if evidence of underlying atherosclerotic disease is present.

Previous
Next

Intraoperative Details

Although peripheral arterial disease is a diffuse process, the preponderance of findings can often be attributed to a particular segment of the arterial tree. Angiographic findings combined with knowledge of the patient's symptoms, physical findings, and noninvasive laboratory results leads the vascular specialist to determine which artery or arteries are best treated by invasive means.[42]

This determination is not an exact science, and it is not unusual for the vascular specialist to correct a single lesion and then discover that the recurring symptoms dictate another procedure at a later date. Nonetheless, attempting to correct all diseased segments at once usually confers too high an operative risk.

Disease of the iliac artery

Hemodynamically significant disease involving the iliac arteries, particularly short-segment stenotic and even occlusive disease, can usually be successfully treated with percutaneous angioplasty, percutaneous insertion of an arterial stent, or both.[43]

If endovascular reconstruction is not possible, femorofemoral crossover bypass is usually the best choice for unilateral iliac artery occlusion, and aortobifemoral bypass is usually the best choice for bilateral or diffuse aortoiliac disease.

Axillofemoral bypass is an alternative in high-risk patients who cannot tolerate an intra-abdominal or retroperitoneal operation (see Aortoiliac Occlusive Disease).

Disease involving the femoral artery

Hemodynamically significant disease involving the femoral artery is usually the result of relatively long-segment occlusion of the distal superficial femoral artery in the adductor canal.

Endovascular approaches to infrainguinal disease have become increasingly successful. Secondary interventions are often required, but assisted patency rates are reported as over 90% in appropriately selected patients.

Correction of this type of disease often requires bypass from a pulsatile distal common femoral artery to the pulseless popliteal artery. Such a bypass is best performed by using the ipsilateral great (long) saphenous vein. If this vein is not suitable or has been used previously, alternative conduits for above-the-knee bypasses include expanded polytetrafluoroethylene (ePTFE) prosthetic graft, Dacron graft, tanned bovine umbilical vein graft, and glutaraldehyde-tanned human umbilical vein.[44]

Because of inferior patency rates with prosthetic grafts extending below the knee, the vascular surgeon usually tries to locate a usable autologous vein from the contralateral lower extremity by combining available short segments from both sides, upper-extremity veins, or even composite grafts (in which a prosthetic graft extends to the knee and a piece of autologous vein is attached distally or when a vein patch is used to attach the prosthetic graft to the distal artery).

In a study of diabetic patients with critical limb ischemia, autologous saphenous vein operations for below-the-knee bypasses were superior to ePTFE grafts in terms of primary patency. However, secondary patency rates were not statistically different between the two procedures, and limb salvage rates were comparable.[45]

Angioplasty with or without stenting may be appropriate for short-segment superficial femoral artery occlusive disease.

Disease involving the infrapopliteal arterial tree

Extensive disease involving the infrapopliteal segments is best managed by means of autologous vein grafting. Arguably, the best technique is the use of the ipsilateral saphenous vein in situ.

This is a somewhat tedious procedure in which the saphenous vein is first disconnected from the femoral vein in the groin and anastomosed to the common femoral artery. The vein is then transected distally, and a valvulotome is inserted retrograde and withdrawn so as to destroy the valves that would have prevented arterial flow from the groin to the leg in the vein.

Next, an anastomosis is created between the distal end of the vein and a usable small artery, even as far distally as the dorsalis pedis at the ankle or foot. Finally, the vein branches are ligated to stop arteriovenous flow.

Patients must be selected carefully for this technique. The vein must be patent and of adequate length and caliber, and a usable, soft distal artery must be available. Preoperative vein mapping using duplex scanning is sometimes helpful.

Endovascular procedures

Percutaneous transluminal angioplasty is often appropriate for strictures or short-segment occlusions of the superficial femoral, popliteal, and, occasionally, infrapopliteal arteries.[46, 4, 47] Angioplasty is performed by passing a guide wire through the lumen of the strictured artery and then advancing a balloon angioplasty catheter over the guidewire. The balloon is inflated to several atmospheres of pressure under angiographic visualization. This effectively disrupts the plaque and provides a wider, patent lumen.

Although angioplasty has been used increasingly for claudication, whether the risks justify the benefits for many patients in this group is a serious question.[48] In a randomized controlled trial, Bradbury et al found that angioplasty has a high failure rate (~25%) in patients with severe limb ischemia from infrainguinal occlusive disease and that patients who underwent bypass after failed angioplasty fared significantly worse than those who underwent surgery as their first procedure.[49]

Nevertheless, Bradbury et al suggested that in patients with severe limb ischemia whose life expectancy is less than 2 years, balloon angioplasty should usually be offered before bypass surgery, as it is associated with less morbidity and cost, and such patients are unlikely to enjoy the longer-term benefits of surgery.[49]

In patients who are expected to live beyond 2 years, bypass surgery should usually be offered first, especially where a vein is available as a conduit. However, patients who cannot undergo a vein bypass may often be better served by a first attempt at balloon angioplasty than prosthetic bypass.

Somewhat surprisingly, even if the guide wire cannot negotiate the lumen of a stricture and instead passes through the subintimal plane, subintimal (extraluminal) angioplasty may succeed.[50] This method seems to create a new channel in a virgin plane. Low echogenicity at the distal end of the plaque, as measured by duplex ultrasound–derived gray-scale median, seems to increase the chance of successful subintimal angoplasy.[51]

Chronic total occlusions of infrainguinal vessels may be resistant to conventional guide-wire techniques. In the PATRIOT trial, which included 85 patients with a previous or concurrent failed attempt to cross such an occlusion with a standard guide-wire approach, Laird et al found that the Crosser chronic total occlusion recanalization system facilitated the crossing of chronic infrainguinal occlusions that were resistant to guide-wire crossing, while posing only a minimal risk of clinically significant vessel perforation.[52]

Angioplasty may be combined with percutaneous stenting. Self-expanding nickel-titanium alloy (nitinol) stents have demonstrated a 2-year primary patency rate of 47% and a limb salvage rate of 66% when used to treat limb ischemia.[53]

Despite the success of drug-eluting stents in the coronary circulation, initial reports using drug-eluting stents in the peripheral circulation have been disappointing. However, European investigators have documented success with a slow-release everolimus stent to prevent restenosis following peripheral arterial intervention.

The first-in-human Superficial Femoral Artery Treatment with Drug-Eluting Stents (STRIDES) trial showed primary patency (freedom from ≥50% in-stent restenosis) rates of 94 ± 2.3% and 68 ± 4.6% at 6 and 12 months, respectively, for the treatment of symptomatic superficial femoral and proximal popliteal arterial occlusive disease.[54]

In addition to intra-procedure anticoagulation, patients are typically treated with an antiplatelet agent, such as clopidogrel, both before and for a month or more postprocedure.[53]

Percutaneous endovascular removal of atherosclerotic plaque (ie, atherectomy) seemed quite promising in the early 1990s, but it was abandoned because of very poor long-term success rates. More recently, however, it has garnered some renewed interest in research settings.[55, 56, 57, 58]

Endarterectomy

Removal of atherosclerotic plaque and underlying diseased arterial intima (endarterectomy) at anastomotic sites is sometimes necessary as an adjunct to bypass surgery but is indicated only rarely as the sole management for lower-extremity arterial occlusive disease.

One exception is endarterectomy of the deep femoral artery (profundoplasty), which may be useful in the rare case of severe limb-threatening stenosis of the origin of the deep femoral artery associated with a superficial femoral artery occlusion that cannot be bypassed for technical reasons.

Another indication for endarterectomy is to remove localized embolizing ulcerated plaque.

Management of acute arterial occlusion

The usual immediate management of acute arterial occlusion consists of immediate heparin anticoagulation and rapid surgical thromboembolectomy. If time allows, especially if atherosclerotic thrombosis is suggested, preoperative angiography is often wise. It may provide information vital to performing bypass surgery should thrombectomy disclose severe underlying atherosclerotic disease.

In some cases, particularly very high-risk patients, thrombolytic therapy by selective intra-arterial infusion (if available) is a reasonable alternative to emergency surgery. For infrainguinal acute occlusions, a medial approach to the distal popliteal artery trifurcation is usually the best method to allow complete evaluation and clearance of all outflow vessels.

After relief of an acute arterial occlusion, one must be alert to the possibility of reperfusion complications such as compartment syndrome or myopathic-metabolic-nephrotic syndrome. Compartment syndrome is characterized by tense edema of the leg, which raises interstitial tissue pressures and impedes arterial inflow. Emergency four-compartment fasciotomy can save limbs.

Myopathic-metabolic-nephrotic syndrome is the result of reperfusion of essentially irreversibly ischemic muscle. It is characterized by metabolic acidosis, dark urine, and renal failure. Emergency limb amputation may be required to save the patient's life.

After emergency treatment to salvage the ischemic limb, the clinician must determine the etiology of the acute occlusion. If it was thrombotic, the underlying atherosclerotic disease may require correction. If it was embolic, the source must be sought.

Ninety percent of arterial emboli originate in the heart. The remaining emboli originate in the aorta (see Differential diagnoses) or from venous thrombi that pass into the arterial circulation via a right-to-left intracardiac shunt (paradoxic embolism). Sometimes, the source can be treated, but usually, long-term anticoagulation is required.

Aneurysm resection is indicated for symptomatic, expanding, or sizable popliteal artery aneurysms. A vein graft is usually used to replace the resected or excluded popliteal artery segment. (See Thoracic Aortic Aneurysm.)

Previous
Next

Postoperative Details

Postoperative care after vascular surgery requires in-hospital observation in order to expeditiously detect and treat complications.

Occlusion

The most frequent complication of endovascular and vascular surgical procedures is occlusion. Some authorities recommend the use of antiplatelet therapy (eg, aspirin or clopidogrel) starting before angioplasty or bypass surgery and continuing indefinitely. For grafts considered to be at high risk for thrombosis, such as those with poor runoff, with a previous occlusion, with a prosthetic graft, or in a hypercoagulable state, heparin may be given perioperatively, and warfarin may be administered for long-term prophylaxis.

Acute postoperative thrombosis

Any change in circulatory status beyond the bypass graft warrants a rapid evaluation. If thrombosis has occurred, rapid return to the operating room for thrombectomy and repair is required. In such cases, a technical problem (eg, intimal flap) must be sought.

Normal postoperative recovery

Ambulation with the assistance of a physical therapist usually starts gradually on postoperative day 1 or 2. The timing of hospital discharge varies with the extent of the procedure and the patient's general condition. If bypass surgery has been performed in conjunction with significant distal amputations, recovery in a skilled nursing facility or rehabilitation center may be beneficial.

Management following percutaneous procedures

After percutaneous procedures, the patient is observed from 4 hours to overnight to ensure absolute bed rest and detect possible complications of the puncture and intervention. Antiplatelet therapy is usually prescribed. For patients with renal compromise and those on metformin, check serum creatinine values 1-2 days after the procedure.

Previous
Next

Follow-up

A routine postoperative follow-up assessment is essential, for two reasons.

First, medical management of the underlying atherosclerotic disease must continue.

Second, bypass graft surveillance using noninvasive vascular laboratory testing may help detect problems that can threaten graft patency, such as progressive atherosclerotic disease of inflow or outflow vessels or buildup of scar tissue (neointimal fibrous hyperplasia) at the anastomotic sites. If these problems can be detected before they lead to graft thrombosis, they may be corrected by endovascular means (ie, angioplasty or stenting). Open surgical revision for restenosis of vein grafts, however, carries a higher long-term success rate than percutaneous intervention.[59]

A typical schedule for outpatient follow-up after peripheral arterial intervention is at 2 weeks, 1 month, 3 months, 6 months, and every 6 months thereafter.

Previous
Next

Complications

Important complications of vascular surgery include early postoperative occlusion, hemorrhagic problems, graft infection, cardiac morbidity, and restenosis.

Early postoperative occlusion

Early postoperative arterial or graft occlusion usually occurs as a result of technical factors such as an intimal flap or the use of a suboptimal conduit.[60] Early reocclusion warrants a quick return to the operating room for thrombectomy and repair of any potential technical defect. Unfortunately, the long-term prognosis after a take-back procedure for early graft occlusion is poor, with only approximately one quarter of such grafts still functional 5 years later.

Hemorrhagic problems

Hemorrhage and pseudoaneurysm formation may occur at the arterial puncture site or, less commonly, at a graft suture line. Management of the latter usually requires a return to the operating room for surgical repair; however, endovascular puncture site pseudoaneurysms can sometimes be treated with ultrasound-guided compression repair.[61]

In this technique, guided by continuous duplex scanning, the pseudoaneurysm is compressed just enough to stop flow outside the lumen of the involved artery but still preserve distal arterial flow. This compression continues for approximately 45 minutes, until the pseudoaneurysm thromboses. Arteriovenous fistulas have also been treated using this technique.

Ultrasound-guided percutaneous thrombin injection has also been shown to be quite effective and more expeditious.[62]

Graft infection

Prosthetic graft infections are rare but serious and may require removal of the bypass graft and even amputation of the limb. They occur in approximately 1% of prosthetic graft bypasses. Currently, methicillin-resistant S aureus is the preponderant pathogen.

Treatment usually requires complete removal of the graft and, if possible, reconstruction using a new graft via an extra-anatomic pathway, such as an iliopopliteal bypass from the iliac artery via the obturator foramen to the popliteal artery beyond the infected graft's distal anastomosis.

Cardiac morbidity

Plaque in the superficial femoral artery (SFA) tends to be a late development in patients with generalized atherosclerotic disease. Therefore, the presence of SFA plaque conveys a very high likelihood of coexisting cardiac or carotid atherosclerosis.[63]

Because of this association of atherosclerotic coronary artery disease with peripheral arterial disease, postoperative myocardial events such as cardiac death, nonfatal myocardial infarction, unstable angina, ventricular tachycardia, and congestive heart failure may occur following infrainguinal bypass operations.

Although most studies suggest an overall cardiac complication rate of approximately 5%, one study found that such myocardial events occurred at an alarming rate of 24% in 87 patients undergoing infrainguinal reconstruction.

Restenosis

The most common late complication of both endovascular and vascular reconstructive procedures is restenosis resulting from a proliferation of smooth muscle cells causing an excessively thickened neointima, which can lead to late arterial or graft reocclusion. This is best prevented by routine postoperative graft surveillance and managed by endovascular repair, patch grafting, of bypass revision before occlusion occurs (see Follow-up care). Postoperative statin use may decrease restenosis rates.[64]

Previous
Next

Outcome and Prognosis

Outcome and prognosis are considered separately for patients treated medically and for patients treated surgically.

Medical management

Infrainguinal arterial disease is associated with a risk of limb-threatening ischemia. However, most patients improve with medical treatment. Approximately 10% of patients with intermittent claudication develop findings necessitating vascular reconstructive procedures.

Endovascular management

Patency rates following endovascular treatment of infrainguinal occlusive disease vary significantly among published series. Overall, primary patency is somewhat inferior to that of bypass surgery. Nonetheless, successful endovascular management improves quality of life and patient satisfaction.[65] Furthermore, further endovascular or surgical management can often correct a failed endovascular intervention.[66, 67]

Surgical management

Graft patency rates vary widely among series. One study in which graft patency was assessed by using MRA disclosed an 84% limb salvage rate and a 78% primary graft patency rate at 21 months' follow-up. Prosthetic grafts carry a primary 3-year patency rate of 39% and a 3-year secondary patency rate of 59%, with a 25% risk of amputation within 3 years.[68]

Limb salvage rates are lower among patients with insulin-dependent diabetes.[69] Infrainguinal reconstructive surgery is associated with a mortality of somewhat less than 5% despite the high-risk nature of these patients.[70] The likelihood of coexisting coronary artery disease is a major risk factor.

A British study reports that the major amputation rate after femorodistal bypass remains high, with adverse events occurring after approximately 38% of femoropopliteal procedures and nearly 50% of femorodistal bypasses. The main predictors of a poor outcome reportedly were diabetes and chronic renal failure.[38]

The overall survival rate for patients with lower-extremity arterial occlusive disease is approximately 50% over 10 years. For patients who require bypass surgery, the survival rate drops to approximately 50% over 5 years.

A study by Suckow et al explored associations between statin use and long-term mortality, graft occlusion, and amputation after infrainguinal bypass.[71] The investigators found that such therapy yielded a significant benefit with respect to 5-year survival but did not offer a significant advantage with respect to 1-year amputation or 1-year graft occlusion rates.

Previous
Next

Future and Controversies

Technological enhancements and wider availability of existing technology should continue to improve the safety and efficacy of endovascular and vascular surgical techniques.[72, 73]

Improvements in imaging technology

Imaging technology continues to improve.[74] Three-dimensional (3D) ultrasonographic visualization can help better detect early plaque formation to allow for even more timely correction of vein graft stenoses. Gadolinium-enhanced 3D MRA images can provide highly detailed views of the arterial system. The applications of MRA, including guidance of endovascular interventions,[75] will expand with continuing improvements in hardware, software, and nonnephrotoxic contrast agents.

Improvements in endovascular techniques

Endovascular procedures continue to benefit from improved technology both in imaging modalities and instrumentation.[76] In the performance of an in-situ bypass, endovascular technology allows valvulotomy and coil occlusion of side branches by direct angioscopic visualization.

Endoscopic assistance

As in other surgical fields, endoscopy may have a greater role in infrainguinal vascular surgery. For example, endoscopic harvesting of the saphenous vein limits the extent of the dissection required for bypass procedures.[77]

Arterialization of the distal venous bed

Studies have suggested that in patients with limb-threatening ischemia but inoperably diseased distal arteries, arterialization of the distal venous bed may be of benefit.[66, 78]

Prevention of restenosis

Gene therapy holds promise for inhibiting vascular restenosis after endovascular procedures or bypass surgery. Rat and rabbit models suggest that neointimal hyperplasia after arterial injury is inhibited by overexpression of the GAX gene and that adenovirus-mediated delivery of the GAX gene diminishes proliferation of intimal cells in animal models. Gene therapy may be suitable for vein grafts prior to implantation.

Some research is underway on inhibitors of smooth muscle proliferation, such as drugs that block E2F transcription factors.[3, 79] Unfortunately, a multicenter, randomized, double-blinded study of 1404 patients revealed no benefit from the use of edifoligide, an E2F inhibitor.[80, 81]

Low-dose intravascular beta-irradiation may inhibit restenosis by blocking early medial and adventitial cell proliferation.[82]

New technology

An array of new endovascular devices have been developed for lower-extremity revascularization. These include the following[83] :

  • Catheters to cross chronic total occlusions [52]
  • Reentry device
  • Stent graft
  • Debulking devices (excisional atherectomy, rotational atherectomy, laser)
  • Cryoplasty
  • Embolic protection device
  • Cutting balloon

Development of new technologies and refinement of existing devices will improve the armamentarium of endovascular therapy. The long-term outcome of endovascular treatment compared with open surgical bypass has not yet been sufficiently well studied, and further research is warranted.

Previous
 
Contributor Information and Disclosures
Author

Christian Ochoa, MD Assistant Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine of the University of Southern California

Christian Ochoa, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society

Disclosure: Nothing to disclose.

Coauthor(s)

Tina T Ng, MD Fellow in Vascular Surgery and Endovascular Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Tina T Ng, MD is a member of the following medical societies: American College of Surgeons, Society for Vascular Surgery, Association of Women Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Pacific Coast Surgical Association, Western Vascular Society

Disclosure: Nothing to disclose.

Additional Contributors

William H Pearce, MD Chief, Division of Vascular Surgery, Violet and Charles Baldwin Professor of Vascular Surgery, Department of Surgery, Northwestern University, The Feinberg School of Medicine

William H Pearce, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, American Surgical Association, Association for Academic Surgery, Association of VA Surgeons, Central Surgical Association, New York Academy of Sciences, Society for Vascular Surgery, Society of Critical Care Medicine, Society of University Surgeons, Western Surgical Association

Disclosure: Nothing to disclose.

References
  1. Rectenwald JE, Upchurch GR Jr. Impact of outcomes research on the management of vascular surgery patients. J Vasc Surg. 2007 Jun. 45 Suppl A:A131-40. [Medline].

  2. Brothers TE, Robison JG, Elliott BM. Prospective decision analysis for peripheral vascular disease predicts future quality of life. J Vasc Surg. 2007 Oct. 46(4):701-708; discussion 708. [Medline].

  3. Conte MS, Lorenz TJ, Bandyk DF, Clowes AW, Moneta GL, Seely BL. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovascular Surg. 2005 Jan-Feb. 39(1):15-23. [Medline].

  4. Nolan B, Finlayson S, Tosteson A, Powell R, Cronenwett J. The treatment of disabling intermittent claudication in patients with superficial femoral artery occlusive disease--decision analysis. J Vasc Surg. 2007 Jun. 45(6):1179-84. [Medline].

  5. Baumgartner I, Schainfeld R, Graziani L. Management of peripheral vascular disease. Annu Rev Med. 2005. 56:249-72. [Medline].

  6. Feringa HH, Bax JJ, Hoeks S, van Waning VH, Elhendy A, Karagiannis S. A prognostic risk index for long-term mortality in patients with peripheral arterial disease. Arch Intern Med. 2007 Dec 10. 167(22):2482-9. [Medline].

  7. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006 Feb 1. 295(5):547-53. [Medline].

  8. Chi YW, Jaff MR. Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheter Cardiovasc Interv. 2008 Feb 28. 71(4):475-489. [Medline].

  9. Daskalopoulou SS, Pathmarajah M, Kakkos SK, Daskalopoulos ME, Holloway P, Mikhailidis DP. Association between ankle - brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J. 2008 Mar. 72(3):441-8. [Medline].

  10. Garofolo L, Barros N Jr, Miranda F Jr, D'Almeida V, Cardien LC, Ferreira SR. Association of increased levels of homocysteine and peripheral arterial disease in a Japanese-Brazilian population. Eur J Vasc Endovasc Surg. 2007 Jul. 34(1):23-8. [Medline].

  11. Taute BM, Taute R, Heins S, Behrmann C, Podhaisky H. Hyperhomocysteinemia: marker of systemic atherosclerosis in peripheral arterial disease. Int Angiol. 2004 Mar. 23(1):35-40. [Medline].

  12. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008 Feb 12. 117(6):823-31. [Medline].

  13. Cournot M, Boccalon H, Cambou JP, Guilloux J, Taraszkiewicz D, Hanaire-Broutin H. Accuracy of the screening physical examination to identify subclinical atherosclerosis and peripheral arterial disease in asymptomatic subjects. J Vasc Surg. 2007 Dec. 46(6):1215-21. [Medline].

  14. Reber PU, Patel AG, Stauffer E, et al. Mural aortic thrombi: An important cause of peripheral embolization. J Vasc Surg. 1999 Dec. 30(6):1084-9. [Medline].

  15. Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology (Oxford). 2007 Feb. 46(2):192-9. [Medline].

  16. Stone JH. Vasculitis: a collection of pearls and myths. Rheum Dis Clin North Am. 2007 Nov. 33(4):691-739, v. [Medline].

  17. Kurvers HA. Reflex sympathetic dystrophy: facts and hypotheses. Vasc Med. 1998. 3(3):207-14. [Medline].

  18. Stager A, Clement D. Popliteal artery entrapment syndrome. Sports Med. 1999 Jul. 28(1):61-70. [Medline].

  19. Pham TT, Kapur R, Harwood MI. Exertional leg pain: teasing out arterial entrapments. Curr Sports Med Rep. 2007 Dec. 6(6):371-5. [Medline].

  20. Rispoli P, Moniaci D, Zan S, Cassatella R, Varetto G, Maselli M. Cystic adventitial disease of the popliteal artery. Report of 1 case and review of the literature. J Cardiovasc Surg (Torino). 2003 Apr. 44(2):255-8. [Medline].

  21. Thatipelli MR, Pellikka PA, McBane RD, Rooke TW, Rosales GA, Hodge D. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. J Vasc Surg. 2007 Jul. 46(1):62-70; discussion 70. [Medline].

  22. Yamada T, Ohta T, Ishibashi H, Sugimoto I, Iwata H, Takahashi M. Clinical reliability and utility of skin perfusion pressure measurement in ischemic limbs--comparison with other noninvasive diagnostic methods. J Vasc Surg. 2008 Feb. 47(2):318-23. [Medline].

  23. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents--a new use for an old drug. N Engl J Med. 2000 Jul 20. 343(3):210-2. [Medline].

  24. Penfield JG, Reilly RF Jr. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007 Dec. 3(12):654-68. [Medline]. [Full Text].

  25. Meaney JF, Goyen M. Recent advances in contrast-enhanced magnetic resonance angiography. Eur Radiol. 2007 Mar. 17 Suppl 2:B2-6. [Medline].

  26. Burrill J, Dabbagh Z, Gollub F, Hamady M. Multidetector computed tomographic angiography of the cardiovascular system. Postgrad Med J. 2007 Nov. 83(985):698-704. [Medline].

  27. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep. 26(3):517-38. [Medline].

  28. Aronow WS. Management of peripheral arterial disease. Cardiol Rev. 2005 Mar-Apr. 13(2):61-8. [Medline].

  29. Lumsden AB, Rice TW. Medical management of peripheral arterial disease: a therapeutic algorithm. J Endovasc Ther. 2006 Feb. 13 Suppl 2:II19-29. [Medline].

  30. McDermott MM, Guralnik JM, Ferrucci L, Tian L, Pearce WH, Hoff F. Physical activity, walking exercise, and calf skeletal muscle characteristics in patients with peripheral arterial disease. J Vasc Surg. 2007 Jul. 46(1):87-93. [Medline].

  31. Rice TW, Lumsden AB. Optimal medical management of peripheral arterial disease. Vasc Endovascular Surg. 2006 Aug-Sep. 40(4):312-27. [Medline].

  32. Tulsyan N, Ouriel K, Kashyap VS. Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar. 11(1):75-90. [Medline].

  33. Jacoby D, Mohler ER 3rd. Drug treatment of intermittent claudication. Drugs. 2004. 64(15):1657-70. [Medline].

  34. Robless P, Mikhailidis D, Stansby G. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008. (1):CD003748. [Medline].

  35. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008 Feb. 47(2):330-336. [Medline].

  36. Nolan BW, De Martino RR, Stone DH, et al. Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass. J Vasc Surg. 2011 Sep. 54(3):730-6. [Medline].

  37. Uhl C, Hock C, Betz T, Bröckner S, Töpel I, Steinbauer M. The impact of infrainguinal endovascular interventions on the results of subsequent femoro-tibial bypass procedures: a retrospective cohort study. Int J Surg. 2015 Jan. 13:261-6. [Medline].

  38. Moxey PW, Hofman D, Hinchliffe RJ, Jones K, Thompson MM, Holt PJ. Trends and outcomes after surgical lower limb revascularization in England. Br J Surg. 2011 Oct. 98(10):1373-82. [Medline].

  39. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007 Jan. 45 Suppl S:S5-67. [Medline].

  40. Stone DH, Goodney PP, Schanzer A, et al. Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery. J Vasc Surg. 2011 Sep. 54(3):779-84. [Medline].

  41. Stewart AH, Eyers PS, Earnshaw JJ. Prevention of infection in peripheral arterial reconstruction: a systematic review and meta-analysis. J Vasc Surg. 2007 Jul. 46(1):148-55. [Medline].

  42. Perera GB, Lyden SP. Current trends in lower extremity revascularization. Surg Clin North Am. 2007 Oct. 87(5):1135-47, x. [Medline].

  43. Ichihashi S, Higashiura W, Itoh H, Sakaguchi S, Nishimine K, Kichikawa K. Long-term outcomes for systematic primary stent placement in complex iliac artery occlusive disease classified according to Trans-Atlantic Inter-Society Consensus (TASC)-II. J Vasc Surg. 2011 Apr. 53(4):992-9. [Medline].

  44. Neufang A, Espinola-Klein C, Dorweiler B, Messow CM, Schmiedt W, Vahl CF. Femoropopliteal prosthetic bypass with glutaraldehyde stabilized human umbilical vein (HUV). J Vasc Surg. 2007 Aug. 46(2):280-8. [Medline].

  45. Dorigo W, Pulli R, Castelli P, Dorrucci V, Ferilli F, De Blasis G, et al. A multicenter comparison between autologous saphenous vein and heparin-bonded expanded polytetrafluoroethylene (ePTFE) graft in the treatment of critical limb ischemia in diabetics. J Vasc Surg. 2011 Nov. 54(5):1332-8. [Medline].

  46. DeRubertis BG, Pierce M, Chaer RA, Rhee SJ, Benjeloun R, Ryer EJ. Lesion severity and treatment complexity are associated with outcome after percutaneous infra-inguinal intervention. J Vasc Surg. 2007 Oct. 46(4):709-16. [Medline].

  47. Conrad MF, Cambria RP, Stone DH, Brewster DC, Kwolek CJ, Watkins MT. Intermediate results of percutaneous endovascular therapy of femoropopliteal occlusive disease: a contemporary series. J Vasc Surg. 2006 Oct. 44(4):762-9. [Medline].

  48. Vogel TR, Su LT, Symons RG, Flum DR. Lower extremity angioplasty for claudication: a population-level analysis of 30-day outcomes. J Vasc Surg. 2007 Apr. 45(4):762-7. [Medline].

  49. Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, et al. Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. Health Technol Assess. 2010 Mar. 14(14):1-210, iii-iv. [Medline]. [Full Text].

  50. Scott EC, Biuckians A, Light RE, Scibelli CD, Milner TP, Meier GH 3rd. Subintimal angioplasty for the treatment of claudication and critical limb ischemia: 3-year results. J Vasc Surg. 2007 Nov. 46(5):959-64. [Medline].

  51. Marks NA, Ascher E, Hingorani AP, Shiferson A, Puggioni A. Gray-scale median of the atherosclerotic plaque can predict success of lumen re-entry during subintimal femoral-popliteal angioplasty. J Vasc Surg. 2008 Jan. 47(1):109-15; discussion 115-6. [Medline].

  52. Laird J, Joye J, Sachdev N, Huang P, Caputo R, Mohiuddin I, et al. Recanalization of infrainguinal chronic total occlusions with the crosser system: results of the PATRIOT trial. J Invasive Cardiol. 2014 Oct. 26(10):497-504. [Medline].

  53. Morgan JH 3rd, Wall CE Jr, Christie DB, Harvey RL, Solis MM. The results of superficial femoral, popliteal, and tibial artery stenting for peripheral vascular occlusive disease. Am Surg. 2005 Nov. 71(11):905-9; discussion 909-10. [Medline].

  54. Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011 Aug. 54(2):394-401. [Medline].

  55. Yoffe B, Yavnel L, Altshuler A, et al. Preliminary experience with the Xtrak debulking device in the treatment of peripheral occlusions. J Endovasc Ther. 2002 Apr. 9(2):234-40. [Medline].

  56. Garvin R, Reifsnyder T. Cutting balloon angioplasty of autogenous infrainguinal bypasses: short-term safety and efficacy. J Vasc Surg. 2007 Oct. 46(4):724-30. [Medline].

  57. Zeller T, Rastan A, Schwarzwalder U, et al. Midterm results after atherectomy-assisted angioplasty of below-knee arteries with use of the Silverhawk device. J Vasc Interv Radiol. 2004 Dec. 15(12):1391-7. [Medline].

  58. Zeller T, Rastan A, Schwarzwalder U, et al. Percutaneous peripheral atherectomy of femoropopliteal stenoses using a new-generation device: six-month results from a single-center experience. J Endovasc Ther. 2004 Dec. 11(6):676-85. [Medline].

  59. Berceli SA, Hevelone ND, Lipsitz SR, Bandyk DF, Clowes AW, Moneta GL. Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. J Vasc Surg. 2007 Dec. 46(6):1173-1179. [Medline].

  60. Schanzer A, Hevelone N, Owens CD, Belkin M, Bandyk DF, Clowes AW. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg. 2007 Dec. 46(6):1180-90; discussion 1190. [Medline].

  61. Kumins NH, Landau DS, Montalvo J, Zasadzinski J, Wojciechowski J, Jovanovich BD. Expanded indications for the treatment of postcatheterization femoral pseudoaneurysms with ultrasound-guided compression. Am J Surg. 1998 Aug. 176(2):131-6. [Medline].

  62. Schneider C, Malisius R, Küchler R, Lampe F, Krause K, Bahlmann E. A prospective study on ultrasound-guided percutaneous thrombin injection for treatment of iatrogenic post-catheterisation femoral pseudoaneurysms. Int J Cardiol. 2008 Jan 11. [Medline].

  63. Dalager S, Falk E, Kristensen IB, Paaske WP. Plaque in superficial femoral arteries indicates generalized atherosclerosis and vulnerability to coronary death: an autopsy study. J Vasc Surg. 2008 Feb. 47(2):296-302. [Medline].

  64. Siracuse JJ, Giles KA, Pomposelli FB, Hamdan AD, Wyers MC, Chaikof EL, et al. Long-term results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. J Vasc Surg. 2012 Jan 31. [Medline].

  65. Kalbaugh CA, Taylor SM, Blackhurst DW, Dellinger MB, Trent EA, Youkey JR. One-year prospective quality-of-life outcomes in patients treated with angioplasty for symptomatic peripheral arterial disease. J Vasc Surg. 2006 Aug. 44(2):296-302; discussion 302-3. [Medline].

  66. Gavrilenko AV, Skrylev SI. Long-term results of venous blood flow arterialization of the leg and foot in patients with critical lower limb ischemia. Angiol Sosud Khir. 2007. 13(2):95-103. [Medline].

  67. Ryer EJ, Trocciola SM, DeRubertis B, Lam R, Hynecek RL, Karwowski J. Analysis of outcomes following failed endovascular treatment of chronic limb ischemia. Ann Vasc Surg. 2006 Jul. 20(4):440-6. [Medline].

  68. Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames ML, Johnson BL. The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure. J Vasc Surg. 2007 Dec. 46(6):1160-6. [Medline].

  69. DeRubertis BG, Pierce M, Ryer EJ, Trocciola S, Kent KC, Faries PL. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg. 2008 Jan. 47(1):101-8. [Medline].

  70. Hertzer NR, Bena JF, Karafa MT. A personal experience with the influence of diabetes and other factors on the outcome of infrainguinal bypass grafts for occlusive disease. J Vasc Surg. 2007 Aug. 46(2):271-279. [Medline].

  71. Suckow BD, Kraiss LW, Schanzer A, Stone DH, Kalish J, DeMartino RR, et al. Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survival. J Vasc Surg. 2015 Jan. 61(1):126-33. [Medline]. [Full Text].

  72. Das T. Optimal therapeutic approaches to femoropopliteal artery intervention. Catheter Cardiovasc Interv. 2004 Sep. 63(1):21-30. [Medline].

  73. Rogers JH, Laird JR. Overview of new technologies for lower extremity revascularization. Circulation. 2007 Oct 30. 116(18):2072-85. [Medline].

  74. Perry JT, Statler JD. Advances in vascular imaging. Surg Clin North Am. 2007 Oct. 87(5):975-93, vii. [Medline].

  75. Bock M, Wacker FK. MR-guided intravascular interventions: techniques and applications. J Magn Reson Imaging. 2008 Feb. 27(2):326-38. [Medline].

  76. Williams DM. Engineering improvements in endovascular devices: design and validation. Ann N Y Acad Sci. 2006 Nov. 1085:213-23. [Medline].

  77. Jimenez JC, Lawrence PF. Minimally invasive distal limb bypasses. Techniques and results. J Cardiovasc Surg (Torino). 2006 Aug. 47(4):415-23. [Medline].

  78. Lu XW, Idu MM, Ubbink DT, Legemate DA. Meta-analysis of the clinical effectiveness of venous arterialization for salvage of critically ischaemic limbs. Eur J Vasc Endovasc Surg. 2006 May. 31(5):493-9. [Medline].

  79. Giangrande PH, Zhang J, Tanner A, Eckhart AD, Rempel RE, Andrechek ER. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A. 2007 Aug 7. 104(32):12988-93. [Medline].

  80. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006 Apr. 43(4):742-751; discussion 751. [Medline].

  81. Hoel AW, Conte MS. Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass. Cardiovasc Drug Rev. 2007. 25(3):221-34. [Medline].

  82. Soni AB, Illig KA, Sternbach Y, Anthony P, Jacob P, Reddy G. Benefits of external beam irradiation for peripheral arterial bypass: preliminary report on a phase I study. Int J Radiat Oncol Biol Phys. 2002 Nov 15. 54(4):1174-9. [Medline].

  83. Rogers JH, Laird JR. Overview of new technologies for lower extremity revascularization. Circulation. 2007 Oct 30. 116(18):2072-85. [Medline].

 
Previous
Next
 
Pressure ulcer of heel exacerbated by infrainguinal arterial occlusive disease.
Cyanosis of first toe and dependent rubor of foot, characteristic of arterial insufficiency.
Contrast angiogram showing severe atherosclerotic disease in distal superficial femoral artery.
Table 1. Staging for Chronic Limb Ischemia
Rutherford Category Fontaine Grade Clinical Description Objective Criteria
0 0 Asymptomatic – No hemodynamically significant disease Normal treadmill or reactive hyperemia test
1   Mild claudication Completes treadmill exercise (5 min at 2 mph on 12% incline)



AP* after exercise >50 mm Hg but at least 20 mm Hg lower than resting value



2 I Moderate claudication Between Rutherford categories 1 and 3
3   Severe claudication Cannot complete treadmill exercise and AP after exercise < 50 mm Hg
4 II Ischemic rest pain Resting AP < 40 mm Hg, flat or barely pulsatile ankle or metatarsal PVR**; TP † < 30 mm Hg
5 III Minor tissue loss (nonhealing ulcer, focal gangrene with diffuse pedal ischemia) Resting AP < 60 mm Hg, ankle or metatarsal PVR flat or barely pulsatile; TP < 40 mm Hg
6   Major tissue loss (extending above transmetatarsal level, functional foot no longer salvageable) Same as Rutherford category 5
*AP = Ankle pressure.



**PVR = Pulse volume recording.



† TP = Toe pressure.



Table 2. TASC Classification for Femoral Popliteal Lesions
Type Description
Type A lesions
  • Single lesions ≤10 cm in length
  • Single occlusions ≤5 cm in length
Type B lesions
  • Multiple lesions (stenoses or occlusions), each ≤5 cm
  • Single stenosis or occlusion ≤15 cm not involving the infrageniculate popliteal artery
  • Single or multiple lesions in the absence of continuous tibial vessels to improve inflow for a distal bypass
  • Heavily calcified occlusion ≤5 cm in length
  • Single popliteal stenosis
Type C lesions
  • Multiple stenoses or occlusions totaling >15 cm with or without heavy calcification
  • Recurrent stenoses or occlusions that need treatment after two endovascular interventions
Type D lesions
  • Chronic total occlusions of common femoral artery or superficial femoral artery (>20 cm, involving the popliteal artery)
  • Chronic total occlusion of popliteal artery and proximal trifurcation vessels
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.